Paolo Tarantino, MD, Dana-Farber Cancer Institute, Boston, MA, talks on HER2-low breast cancer. HER2-low is not a distinct subtype of breast cancer but has been shown to be an important biomarker for novel antibody-drug conjugates such as trastuzumab deruxtecan. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

свернуть